Accessibility Menu
Lucid Diagnostics logo

Lucid Diagnostics(NASDAQ) LUCD

Market Cap$183.00MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2021)-92%
5 YearN/A
1 Year-11%
1 Month-17%
$0.87
-3.34%
-0.03Today
After hours$0.87+$0.00 (+0.11%)
Lucid Diagnostics last closing stock price
MetricPriceDate
Last closeUSD 0.872026-07-31
Lucid Diagnostics stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-3.97%USD 0.912026-07-24
1 month-16.99%USD 1.052026-07-01
3 month-20.04%USD 1.092026-05-01
Year to date-20.04%USD 1.092025-12-31
1 year-10.93%USD 0.982025-07-31
3 year-39.89%USD 1.452023-08-01
Since inception-92.34%USD 11.762021-10-14

Lucid Diagnostics Financials at a Glance

Market Cap

$183.00MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$5.13M

Net Income (TTM)

-$45.01M

EPS (TTM)

-$0.47

P/E Ratio

-1.92

Dividend

$0.00

Beta (Volatility)

0.00 (Low)

Price

$0.87

Volume

1,186,139.665

Open

$0.89

Previous Close

$0.87

Daily Range

$0.86 - $0.90

52-Week Range

$0.86 - $1.63

Estimated Earnings Date

Aug 12, 2026

LUCD News

Foolcom-Featured.png

LUCD Reports Results

Motley Fool Markets TeamAug 13, 2025

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Lucid Diagnostics

Lucid helps people with chronic heartburn check for early signs of esophageal cancer. Its main tests use a simple, noninvasive device to collect cells from the throat. These products aim to catch disease early, making treatment easier for patients and doctors.

Products and Services

  • EsoGuard DNA Test: Main product, a lab test that checks for early esophageal cancer; most revenue comes from this service.
  • EsoCheck Cell Collection Device: Swallowable device collects throat cells for testing; used with EsoGuard.
  • Lucid Test Centers: Physical clinics where patients can get tested in person.
  • Telemedicine Program: Online service lets patients order tests and consult doctors remotely.
  • Community Testing Events: Outreach programs offer screening at public events and workplaces.

Growth and Expansion

  • Signed a nationwide contract with the U.S. Department of Veterans Affairs in 2025 for test access.
  • Partnered with Hoag health system in 2025 to expand clinical reach.
  • Launched direct contracting with employers and health systems in 2024-2025.
  • Added to the Russell 2000 and Russell 3000 indexes in June 2025.
  • Expanded mobile and telemedicine testing programs since 2024.

What Makes Lucid Stand Out

Lucid offers the only noninvasive DNA test for early esophageal cancer detection in the U.S. Its technology collects targeted throat cells without surgery or sedation. The company uses multiple channels—clinics, telemedicine, and events—to reach at-risk patients.

Five Things You Need to Know

  • Revenue was $4.7 million in FY 2025, up 8.3% from FY 2024.
  • All revenue comes from diagnostic testing, mainly the EsoGuard test.
  • Net loss was $58.0 million in FY 2025, compared to $45.5 million in FY 2024.
  • Cash was $34.7 million as of December 31, 2025, up from $22.4 million.
  • Ongoing operating losses and negative cash flow raise future funding needs.

Bottom Line

Lucid focuses on early cancer detection for people with chronic heartburn. The company relies on a single product line and faces ongoing financial challenges as it grows.

AI Generated • Apr 16, 2026

Industry

Healthcare Equipment and Supplies

Sector

Health Care

Employees

82

CEO

Lishan Aklog, MD

Website

www.luciddx.com

Headquarters

New York City, NY 10165, US

LUCD Financials

Key Financial Metrics (TTM)

Gross Margin

-40.03%

Operating Margin

-959.64%

Net Income Margin

-876.72%

Return on Equity

-370.21%

Return on Capital

-135.05%

Return on Assets

-132.07%

Earnings Yield

-52.08%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$183.00MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

203.07M

Volume

1.19M

Avg. Volume

1.40M

Financials (TTM)

Gross Profit

-$2.06M

Operating Income

-$49.27M

EBITDA

-$44.12M

Operating Cash Flow

-$46.12M

Capital Expenditure

-$319.00K

Free Cash Flow

-$46.44M

Cash & ST Invst.

$27.88M

Total Debt

$26.80M

Lucid Diagnostics Performance Analysis

Lucid Diagnostics annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 377,000-24.6%
20232023-12-31USD 2,428,000544.0%
20242024-12-31USD 4,346,00079.0%
20252025-12-31USD 4,706,0008.3%
Lucid Diagnostics sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-3040.5%
Q32025-09-304.1%
Q42025-12-3124.2%
Q12026-03-31-16.5%
Lucid Diagnostics annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -1.5593.1%
20232023-12-31USD -1.26-18.8%
20242024-12-31USD -1.05-16.8%
20252025-12-31USD -0.69-34.1%
Lucid Diagnostics sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-3084.7%
Q32025-09-30-20.6%
Q42025-12-31-24.9%
Q12026-03-31-41.7%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

$1.26M

+51.7%

Gross Profit

-$591.00K

+18.3%

Gross Margin

-47.05%

N/A

Market Cap

$183.00MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$2.23M

N/A

Employees

82

N/A

Net Income

-$13.91M

+48.3%

EBITDA

-$13.68M

+48.7%

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Total Cash

$27.88M

+10.5%

Total Debt

$26.80M

-24.0%

Accounts Receivable

$689.00K

+1029.5%

Inventory

$1.00M

+106.8%

Long Term Debt

$695.00K

-56.6%

Short Term Debt

$26.11M

-22.5%

Return on Assets

-1.32%

N/A

Return on Invested Capital

-10.49%

N/A

Free Cash Flow

-$12.32M

+1.9%

Operating Cash Flow

-$12.10M

+2.9%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
APYXApyx Medical Corporation
$4.10-0.49%
SEERSeer, Inc.
$2.22+7.77%
RCELAvita Medical Inc.
$4.40-2.00%
RPIDRapid Micro Biosystems, Inc.
$2.13+0.95%

Trending Stocks

Symbol / CompanyPricePrice Chg
NVDANvidia
$200.75+0.03%
AAPLApple
$308.91-0.07%
AMZNAmazon
$271.58+0.15%
INTCIntel
$90.20-0.01%

Questions About LUCD

What is the current price of Lucid Diagnostics?

Lucid Diagnostics is trading at $0.87 per share.

What is the 52-week range for Lucid Diagnostics?

Over the past 52 weeks, Lucid Diagnostics has traded between $0.86 and $1.63.

How much debt does Lucid Diagnostics have?

As of the most recent reporting period, Lucid Diagnostics reported total debt of $26.80M.

How much cash does Lucid Diagnostics have on hand?

Lucid Diagnostics reported $27.88M in cash and cash equivalents in its most recent financial results.

What is Lucid Diagnostics’s dividend yield?

Lucid Diagnostics does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services